{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:18:11Z","timestamp":1794467891863,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"DOI":"10.1186\/s12871-025-03121-y","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T11:43:22Z","timestamp":1748605402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ivabradine use in critical care: a systematic review and metanalysis of cardiogenic and septic shock patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Lorenzo Antonino","family":"Calabr\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pasetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Scolletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Annoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Demailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Halenarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Donadello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Silvio","family":"Taccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"3121_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMra1208943","volume":"369","author":"JL Vincent","year":"2013","unstructured":"Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369:1726\u201334.","journal-title":"N Engl J Med"},{"key":"3121_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1164\/ajrccm.160.2.9810073","volume":"160","author":"D Annane","year":"1999","unstructured":"Annane D, Trabold F, Sharshar T, et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med. 1999;160:458\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"3121_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jcrc.2020.02.014","volume":"57","author":"R Domizi","year":"2020","unstructured":"Domizi R, Calcinaro S, Harris S, et al. Relationship between norepinephrine dose, tachycardia and outcome in septic shock: a multicentre evaluation. J Crit Care. 2020;57:185\u201390.","journal-title":"J Crit Care"},{"key":"3121_CR4","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.2023.20134","volume":"330","author":"T Whitehouse","year":"2023","unstructured":"Whitehouse T, Hossain A, Perkins GD, et al. Landiolol and organ failure in patients with septic shock: the STRESS-L randomized clinical trial. JAMA. 2023;330:1641\u201352.","journal-title":"JAMA"},{"key":"3121_CR5","first-page":"CD009669","volume":"1","author":"J Schumann","year":"2018","unstructured":"Schumann J, Henrich EC, Strobl H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1:CD009669.","journal-title":"Cochrane Database Syst Rev"},{"key":"3121_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1074248414559838","volume":"20","author":"JC Jentzer","year":"2015","unstructured":"Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther. 2015;20:249\u201360.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"3121_CR7","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895\u20131032.","journal-title":"Circulation"},{"key":"3121_CR8","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","volume":"70","author":"JS Koruth","year":"2017","unstructured":"Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of Ivabradine. J Am Coll Cardiol. 2017;70:1777\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"3121_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1476-5381.1995.tb14971.x","volume":"115","author":"SM Gardiner","year":"1995","unstructured":"Gardiner SM, Kemp PA, March JE, Bennett T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol. 1995;115:579\u201386.","journal-title":"Br J Pharmacol"},{"key":"3121_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00392-010-0208-9","volume":"99","author":"D Vitale","year":"2010","unstructured":"Vitale D, De Santis V, Guarracino F, Fontana A, Pellegrini F, Tritapepe L. Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery. Clin Res Cardiol. 2010;99:853\u20135.","journal-title":"Clin Res Cardiol"},{"key":"3121_CR11","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"3121_CR12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"3121_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40261-016-0424-9","volume":"36","author":"F Barilla","year":"2016","unstructured":"Barilla F, Pannarale G, Torromeo C, et al. Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study. Clin Drug Investig. 2016;36:849\u201356.","journal-title":"Clin Drug Investig"},{"key":"3121_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/ehjacc\/zuac133","volume":"11","author":"CNJ Colombo","year":"2022","unstructured":"Colombo CNJ, Dammassa V, Klersy C, et al. Heart rate control and haemodynamic improvement with ivabradine in cardiogenic shock patient on mechanical circulatory support. Eur Heart J Acute Cardiovasc Care. 2022;11:916\u201321.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"3121_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0310057X211009913","volume":"49","author":"PK Datta","year":"2021","unstructured":"Datta PK, Rewari V, Ramachandran R, et al. Effectiveness of enteral ivabradine for heart rate control in septic shock: a randomised controlled trial. Anaesth Intensive Care. 2021;49:366\u201378.","journal-title":"Anaesth Intensive Care"},{"key":"3121_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijcard.2014.07.093","volume":"176","author":"R Gallet","year":"2014","unstructured":"Gallet R, Ternacle J, Damy T, et al. Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction. Int J Cardiol. 2014;176:450\u20135.","journal-title":"Int J Cardiol"},{"key":"3121_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13054-018-2124-8","volume":"22","author":"LS Nguyen","year":"2018","unstructured":"Nguyen LS, Squara P, Amour J, et al. Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial. Crit Care. 2018;22:193.","journal-title":"Crit Care"},{"key":"3121_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/SHK.0000000000000992","volume":"49","author":"S Nuding","year":"2018","unstructured":"Nuding S, Schroder J, Presek P, et al. Reducing elevated heart rates in patients with multiple organ dysfunction syndrome with the If (Funny Channel Current) inhibitor Ivabradine. Shock. 2018;49:402\u201311.","journal-title":"Shock"},{"key":"3121_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000318530","volume":"116","author":"C Zwicker","year":"2010","unstructured":"Zwicker C, Becker M, Lepper W, Koch KC, Westenfeld R. Cardiogenic shock due to tachycardiomyopathy after heart transplantation: successful treatment with ivabradine. Cardiology. 2010;116:174\u20137.","journal-title":"Cardiology"},{"key":"3121_CR20","doi-asserted-by":"publisher","first-page":"203690","DOI":"10.1155\/2011\/203690","volume":"2011","author":"J Franke","year":"2011","unstructured":"Franke J, Schmahl D, Lehrke S, et al. Adjuvant use of ivabradine in acute heart failure due to myocarditis. Case Rep Med. 2011;2011:203690.","journal-title":"Case Rep Med"},{"key":"3121_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00392-014-0722-2","volume":"103","author":"V De Santis","year":"2014","unstructured":"De Santis V, Frati G, Greco E, Tritapepe L. Ivabradine: a preliminary observation for a new terapeutic role in patients with multiple organ dysfunction syndrome. Clin Res Cardiol. 2014;103:831\u20134.","journal-title":"Clin Res Cardiol"},{"key":"3121_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/0885066609340519","volume":"24","author":"MW Dunser","year":"2009","unstructured":"Dunser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. 2009;24:293\u2013316.","journal-title":"J Intensive Care Med"},{"key":"3121_CR23","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00134-016-4249-z","volume":"42","author":"DT Andreis","year":"2016","unstructured":"Andreis DT, Singer M. Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med. 2016;42:1387\u201397.","journal-title":"Intensive Care Med"},{"key":"3121_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1053\/j.jvca.2019.10.017","volume":"34","author":"A Belletti","year":"2020","unstructured":"Belletti A, Landoni G, Lomivorotov VV, Oriani A, Ajello S. Adrenergic downregulation in critical care: molecular mechanisms and therapeutic evidence. J Cardiothorac Vasc Anesth. 2020;34:1023\u201341.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"3121_CR25","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jama.2013.278477","volume":"310","author":"A Morelli","year":"2013","unstructured":"Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683\u201391.","journal-title":"JAMA"},{"key":"3121_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/MCC.0000000000000822","volume":"27","author":"D De Backer","year":"2021","unstructured":"De Backer D, Arias Ortiz J, Levy B. The medical treatment of cardiogenic shock: cardiovascular drugs. Curr Opin Crit Care. 2021;27:426\u201332.","journal-title":"Curr Opin Crit Care"},{"key":"3121_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875\u201385.","journal-title":"Lancet"},{"key":"3121_CR28","doi-asserted-by":"publisher","first-page":"2464274","DOI":"10.1080\/24734306.2025.2464274","volume":"9","author":"MN Bin Sumarni","year":"2025","unstructured":"Bin Sumarni MN, Chiew AL, Isbister GK, Wylie CJ, Isoardi KZ. Ivabradine poisoning: a retrospective observational case series. Toxicol Commun. 2025;9:2464274.","journal-title":"Toxicol Commun"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-025-03121-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-025-03121-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-025-03121-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T11:43:23Z","timestamp":1748605403000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-025-03121-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3121"],"URL":"https:\/\/doi.org\/10.1186\/s12871-025-03121-y","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}